Effect of {sup 18}F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer

Journal Article · Tue Jul 01 04:00:00 EDT 2008 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2008.02.056· OSTI ID:21124306

Groheux, David ^[1]; Moretti, Jean-Luc ^[1]; Baillet, Georges ^[1]; Espie, Marc; Giacchetti, Sylvie ^[2]; Hindie, Elif ^[1]; Hennequin, Christophe ^[3]; Vilcoq, Jacques-Robert ^[4]; Cuvier, Caroline ^[2]; Toubert, Marie-Elisabeth ^[1]; Filmont, Jean-Emmanuel ^[1]; Sarandi, Farid ^[1]; Misset, Jean-Louis ^[2]

---

1. Department of Nuclear Medicine, Breast Diseases Unit, Saint Louis Hospital, Paris (France)
2. Department of Medical Oncology, Breast Diseases Unit, Saint Louis Hospital, Paris (France)
3. EAD Imagerie Moleculaire Diagnostique et Ciblage Therapeutique, IUH, University of Paris VII, Paris (France)
4. Department of Radiation Oncology, Hartmann Hospital, Neuilly sur Seine (France)

Purpose: To investigate the potential effect of using {sup 18}F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in the initial assessment of patients with clinical Stage II or III breast cancer. Methods and Materials: During 14 consecutive months, 39 patients (40 tumors) who presented with Stage II or III breast cancer on the basis of a routine extension assessment were prospectively included in this study. PET/CT was performed in addition to the initial assessment. Results: In 3 cases, PET/CT showed extra-axillary lymph node involvement that had not been demonstrated with conventional techniques. Two of these patients had hypermetabolic lymph nodes in the subpectoral and infraclavicular regions, and the third had a hypermetabolic internal mammary node. PET/CT showed distant uptake in 4 women. Of these 4 women, 1 had pleural involvement and 3 had bone metastasis. Overall, of the 39 women, the PET/CT results modified the initial stage in 7 (18%). The modified staging altered the treatment plan for 5 patients (13%). It led to radiotherapy in 4 patients (bone metastasis, pleural lesion, subpectoral lymph nodes, and internal mammary nodes) and excision of, and radiotherapy to, the infraclavicular lymph nodes in 1 patient. Conclusions: PET/CT can provide information on extra-axillary lymph node involvement and can uncover occult distant metastases in a significant percentage of patients. Therefore, initial PET/CT could enable better treatment planning for patients with Stage II and III breast cancer.

• OSTI ID: 21124306
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 3 Vol. 71; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
FLUORINE 18
FLUORODEOXYGLUCOSE
LYMPH NODES
MAMMARY GLANDS
METASTASES
NEOPLASMS
PATIENTS
POSITRON COMPUTED TOMOGRAPHY
RADIOTHERAPY
SKELETON